{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T02:24:19Z","timestamp":1772159059854,"version":"3.50.1"},"reference-count":53,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,2]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>The impact of immunotherapy has grown exponentially in the past 5 years. Principle illustrations are encouraging results with engineered T cells expressing a chimeric antigen receptor (CAR). This experimental therapy is developing simultaneously in pediatric and adult clinical trials, making this field particularly relevant and exciting for pediatric oncologists.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>CAR-modified T cells targeting CD19 have produced dramatic antitumor responses in patients with relapsed\/refractory B cell acute lymphoblastic leukemia. Clinical trials from several institutions, in both children and adults, using distinct CAR T cell products have demonstrated similar high complete remission rates of 61\u201393%, with durable remissions observed. Although the development of CARs for other malignancies has lagged behind, research into novel approaches to overcome inherent challenges is promising.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Clinical trials of CAR-modified T cells have produced unprecedented results and are anticipated to have a broader impact as this approach expands into other indications, including other cancers and frontline therapy. The potential for long-term disease control, if fully realized, will have a transformative impact on the field.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mop.0000000000000436","type":"journal-article","created":{"date-parts":[[2016,11,11]],"date-time":"2016-11-11T12:00:12Z","timestamp":1478865612000},"page":"27-33","source":"Crossref","is-referenced-by-count":18,"title":["Future directions in chimeric antigen receptor T cell therapy"],"prefix":"10.1097","volume":"29","author":[{"given":"Shannon L.","family":"Maude","sequence":"first","affiliation":[{"name":"Division of Oncology, Cancer Immunotherapy Program, The Children's Hospital of Philadelphia"},{"name":"Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230918","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1073\/pnas.90.2.720","article-title":"Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors","volume":"90","author":"Eshhar","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R2-20230918","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1182\/blood-2011-04-348540","article-title":"Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias","volume":"118","author":"Brentjens","year":"2011","journal-title":"Blood"},{"key":"R3-20230918","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/PPO.0000000000000028","article-title":"4-1BB chimeric antigen receptors","volume":"20","author":"Campana","year":"2014","journal-title":"Cancer J"},{"key":"R4-20230918","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1146\/annurev-med-060512-150254","article-title":"Chimeric antigen receptor therapy for cancer","volume":"65","author":"Barrett","year":"2014","journal-title":"Annu Rev Med"},{"key":"R5-20230918","doi-asserted-by":"crossref","first-page":"132ra153","DOI":"10.1126\/scitranslmed.3003761","article-title":"Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells","volume":"4","author":"Scholler","year":"2012","journal-title":"Sci Transl Med"},{"key":"R6-20230918","doi-asserted-by":"crossref","first-page":"5332","DOI":"10.1182\/blood-2010-09-306761","article-title":"Lentiviral vector common integration sites in preclinical models and a clinical trial reflect a benign integration bias and not oncogenic selection","volume":"117","author":"Biffi","year":"2011","journal-title":"Blood"},{"key":"R7-20230918","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/978-1-62703-260-5_12","article-title":"Nonviral RNA transfection to transiently modify T cells with chimeric antigen receptors for adoptive therapy","volume":"969","author":"Riet","year":"2013","journal-title":"Methods Mol Biol"},{"key":"R8-20230918","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1089\/hum.2013.075","article-title":"Regimen-specific effects of RNA-modified chimeric antigen receptor T cells in mice with advanced leukemia","volume":"24","author":"Barrett","year":"2013","journal-title":"Hum Gene Ther"},{"key":"R9-20230918","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/nbt955","article-title":"The ABCs of artificial antigen presentation","volume":"22","author":"Kim","year":"2004","journal-title":"Nat Biotechnol"},{"key":"R10-20230918","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1089\/scd.1.1998.7.437","article-title":"Large-scale production of CD4+ T cells from HIV-1-infected donors after CD3\/CD28 costimulation","volume":"7","author":"Levine","year":"1998","journal-title":"J Hematother"},{"key":"R11-20230918","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/leu.2015.247","article-title":"Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo","volume":"30","author":"Sommermeyer","year":"2016","journal-title":"Leukemia"},{"key":"R12-20230918","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1182\/blood-2015-12-686725","article-title":"Phase 1 studies of central memory\u2013derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL","volume":"127","author":"Wang","year":"2016","journal-title":"Blood"},{"key":"R13-20230918","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3109\/10428199509059636","article-title":"CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy","volume":"18","author":"Scheuermann","year":"1995","journal-title":"Leuk Lymphoma"},{"key":"R14-20230918","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N Engl J Med"},{"key":"R15-20230918","doi-asserted-by":"crossref","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci Transl Med"},{"key":"R16-20230918","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"key":"R17-20230918","first-page":"3011","article-title":"Sustained remissions with CD19-specific chimeric antigen receptor (CAR)-modified T cells in children with relapsed\/refractory ALL","volume":"34","author":"Maude","year":"2016","journal-title":"ASCO Meeting Abstracts"},{"key":"R18-20230918","first-page":"7002","article-title":"Optimizing chimeric antigen receptor (CAR) T cell therapy for adult patients with relapsed or refractory (r\/r) acute lymphoblastic leukemia (ALL)","volume":"34","author":"Frey","year":"2016","journal-title":"ASCO Meeting Abstracts"},{"key":"R19-20230918","doi-asserted-by":"crossref","first-page":"224ra225","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Transl Med"},{"key":"R20-20230918","first-page":"7003","article-title":"Impact of disease burden on long-term outcome of 19-28z CAR modified T cells in adult patients with relapsed B-ALL","volume":"34","author":"Park","year":"2016","journal-title":"ASCO Meeting Abstracts"},{"key":"R21-20230918","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"key":"R22-20230918","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1182\/blood.V126.23.684.684","article-title":"Safety and response of incorporating CD19 chimeric antigen receptor T cell therapy in typical salvage regimens for children and young adults with acute lymphoblastic leukemia","volume":"126","author":"Lee","year":"2015","journal-title":"Blood"},{"key":"R23-20230918","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J Clin Invest"},{"key":"R24-20230918","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","article-title":"Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy","volume":"5","author":"Sotillo","year":"2015","journal-title":"Cancer Discov"},{"key":"R25-20230918","first-page":"7","article-title":"CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity","author":"Jacoby","year":"2016","journal-title":"Nat Commun"},{"key":"R26-20230918","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1182\/blood-2015-08-665547","article-title":"Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy","volume":"127","author":"Gardner","year":"2016","journal-title":"Blood"},{"key":"R27-20230918","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/PPO.0000000000000035","article-title":"Managing cytokine release syndrome associated with novel T cell-engaging therapies","volume":"20","author":"Maude","year":"2014","journal-title":"Cancer J"},{"key":"R28-20230918","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med"},{"key":"R29-20230918","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"R30-20230918","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"key":"R31-20230918","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","article-title":"Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"6","author":"Teachey","year":"2016","journal-title":"Cancer Discov"},{"key":"R32-20230918","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1182\/blood-2015-03-633685","article-title":"Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232","volume":"126","author":"Borowitz","year":"2015","journal-title":"Blood"},{"key":"R33-20230918","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/bjh.12691","article-title":"Antibody therapy for acute myeloid leukaemia","volume":"164","author":"Gasiorowski","year":"2014","journal-title":"Br J Haematol"},{"key":"R34-20230918","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1038\/leu.2014.62","article-title":"Chimeric antigen receptors against CD33\/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo","volume":"28","author":"Pizzitola","year":"2014","journal-title":"Leukemia"},{"key":"R35-20230918","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1182\/blood-2013-09-529537","article-title":"Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells","volume":"123","author":"Gill","year":"2014","journal-title":"Blood"},{"key":"R36-20230918","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1038\/mt.2016.116","article-title":"CD123-engager T cells as a novel immunotherapeutic for acute myeloid leukemia","volume":"24","author":"Bonifant","year":"2016","journal-title":"Mol Ther"},{"key":"R37-20230918","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.leukres.2015.12.003","article-title":"CD123 redirected multiple virus-specific T cells for acute myeloid leukemia","volume":"41","author":"Zhou","year":"2016","journal-title":"Leukemia Res"},{"key":"R38-20230918","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1038\/leu.2015.52","article-title":"CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia","volume":"29","author":"Kenderian","year":"2015","journal-title":"Leukemia"},{"key":"R39-20230918","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3324\/haematol.2014.112748","article-title":"Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia","volume":"100","author":"O\u2019Hear","year":"2015","journal-title":"Haematologica"},{"key":"R40-20230918","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1182\/blood-2012-12-474056","article-title":"T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia","volume":"122","author":"Mardiros","year":"2013","journal-title":"Blood"},{"key":"R41-20230918","doi-asserted-by":"crossref","first-page":"275ra222","DOI":"10.1126\/scitranslmed.aaa4963","article-title":"Rational development and characterization of humanized anti\u2013EGFR variant III chimeric antigen receptor T cells for glioblastoma","volume":"7","author":"Johnson","year":"2015","journal-title":"Sci Transl Med"},{"key":"R42-20230918","doi-asserted-by":"crossref","first-page":"3596","DOI":"10.1158\/0008-5472.CAN-15-0159","article-title":"Affinity-tuned ErbB2 or EGFR chimeric antigen receptor T cells exhibit an increased therapeutic index against tumors in mice","volume":"75","author":"Liu","year":"2015","journal-title":"Cancer Res"},{"key":"R43-20230918","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1158\/0008-5472.CAN-15-0139","article-title":"Tuning sensitivity of CAR to EGFR density limits recognition of normal tissue while maintaining potent antitumor activity","volume":"75","author":"Caruso","year":"2015","journal-title":"Cancer Res"},{"key":"R44-20230918","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3389\/fphar.2014.00235","article-title":"The inducible caspase-9 suicide gene system as a \u2018safety switch\u2019 to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells","volume":"5","author":"Gargett","year":"2014","journal-title":"Front Pharmacol"},{"key":"R45-20230918","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/978-1-62703-260-5_12","article-title":"Nonviral RNA transfection to transiently modify T cells with chimeric antigen receptors for adoptive therapy","volume":"969","author":"Riet","year":"2013","journal-title":"Methods Mol Biol"},{"key":"R46-20230918","doi-asserted-by":"crossref","first-page":"e458","DOI":"10.1038\/bcj.2016.61","article-title":"Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts","volume":"6","author":"Cartellieri","year":"2016","journal-title":"Blood Cancer J"},{"key":"R47-20230918","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.pharmthera.2016.06.010","article-title":"Chimeric antigen receptor-modified T cells for the treatment of solid tumors: defining the challenges and next steps","volume":"166","author":"Beatty","year":"2016","journal-title":"Pharmacol Ther"},{"key":"R48-20230918","doi-asserted-by":"crossref","first-page":"16006","DOI":"10.1038\/mto.2016.6","article-title":"Chimeric antigen receptor T-cell therapy for solid tumors","volume":"3","author":"Newick","year":"2016","journal-title":"Mol Ther Oncolytics"},{"key":"R49-20230918","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/mt.2016.63","article-title":"GD2-specific CAR T cells undergo potent activation and deletion following antigen encounter but can be protected from activation-induced cell death by PD-1 blockade","volume":"24","author":"Gargett","year":"2016","journal-title":"Mol Ther"},{"key":"R50-20230918","doi-asserted-by":"crossref","first-page":"5636","DOI":"10.1158\/1078-0432.CCR-13-0458","article-title":"Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells","volume":"19","author":"John","year":"2013","journal-title":"Clin Cancer Res"},{"key":"R51-20230918","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1172\/JCI83092","article-title":"Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition","volume":"126","author":"Cherkassky","journal-title":"J Clin Invest"},{"key":"R52-20230918","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1158\/0008-5472.CAN-15-2524","article-title":"A chimeric switch-receptor targeting PD1 augments the efficacy of second-generation CAR T cells in advanced solid tumors","volume":"76","author":"Liu","year":"2016","journal-title":"Cancer Res"},{"key":"R53-20230918","doi-asserted-by":"crossref","first-page":"e200","DOI":"10.1097\/MPH.0b013e318290c3d6","article-title":"Outcome of children and adolescents with a second or third relapse of acute lymphoblastic leukemia (ALL): a population-based analysis of the Austrian ALL-BFM (Berlin-Frankfurt-Munster) study group","volume":"35","author":"Reismuller","year":"2013","journal-title":"J Pediatr Hematol Oncol"}],"container-title":["Current Opinion in Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00008480-201702000-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T02:04:59Z","timestamp":1695002699000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00008480-201702000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/mop.0000000000000436","relation":{},"ISSN":["1040-8703","1531-698X"],"issn-type":[{"value":"1040-8703","type":"print"},{"value":"1531-698X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2]]}}}